Glucuronidation is a major pathway for detoxification in the liver. Drugs and toxic chemicals are conjugated with glucuronide acid to be inactive form through this pathway. However, when glucuronide conjugates enter the intestine, they are reactivated by E. coli expressing G (eG) back to toxic form, thus damaging the intestine and inducing diarrhea, which is likely to cause carcinogenesis and colorectal cancer. The current treatment is using antidiarrheal agent to release the diarrhea symptom but the damage still persist. In addition, there are no clinical drug been developed to prevent colon cancer. In order to meet the unmet clinical need, we have successfully developed eβG specific inhibitor as a novel drug for preventing chemical-induced damage and colon cancer. The inhibitor can be developed as:
1.Chemotherapy adjuvant, be combined with chemo drug to prevent chemotherapy -induced intestinal damage and diarrhea, thus improving patients’ quality of life and increasing patient’s drug tolerance to increase therapy efficacy.
2.Chemoprevention drug, to prevent reactivating of the carcinogen in the intestine and thus reducing chemo-induced carcinogenesis and colon cancer.
We have applied the novel inhibitor and its derivatives and their function for patent protection, including PCT, provisional application for patent in the US, and the Taiwan (ROC) patent.

此腸道菌eβG專一性抑制劑是一個標靶預防藥物，其可專一性抑制腸道菌eβG活性，降低葡萄醣醛酸化的代謝物在腸道內的再度回復毒性，達到保護腸道，預防腸道損傷與大腸癌。此腸道菌eβG專一性抑制劑，具備下列六大特點：(1)專一性抑制腸道菌eβG，(2)不影響益生菌生長，(3)僅作用在腸道，(4)廣泛應用於避免藥物對腸道破壞及腹瀉，(5)不影響藥物治療療效，(6)可預防大腸癌。

本腸道菌eβG專一性抑制劑可阻止肝解毒之藥物或致癌劑於腸道再度活化，造成腸道刺激、損傷最後形成大腸癌。並可應用於:
(1)化療藥口服佐劑，預防化療腸道破壞並改善療效
防止化療藥物於腸道再度活化，造成腸道破壞、腹瀉或血便的副作用。防止病人因嚴重之副作用導致停藥的情形，使病人可以完成治療療程，達到最好的治療效果。
(2)預防大腸癌創新藥物
防止致癌劑於腸道回復毒性，造成腸道病變與大腸癌。預防大腸癌發生，是以預防醫學為主要市場。